Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advanced Therapy for Hepatitis C [[electronic resource]]
| Advanced Therapy for Hepatitis C [[electronic resource]] |
| Autore | McCaughan Geoffrey W |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (233 p.) |
| Disciplina |
616.3/62306
616.362306 |
| Altri autori (Persone) |
McHutchisonJohn
PawlotskyJean-Michel |
| Soggetto topico |
Antiviral agents
Antiviral Agents - therapeutic use Antiviral Agents -- therapeutic use Hepatitis C - therapy Hepatitis C -- therapy Hepatitis C - Treatment Hepatitis C -- Treatment Hepatitis, Viral, Human Flaviviridae Infections Anti-Infective Agents RNA Virus Infections Therapeutic Uses Virus Diseases Hepatitis Diseases Liver Diseases Pharmacologic Actions Chemical Actions and Uses Digestive System Diseases Antiviral Agents Hepatitis C Medicine Health & Biological Sciences Gastroenterology |
| ISBN |
1-283-28323-9
9786613283238 1-4443-4634-2 1-4443-4631-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Advanced Therapy for Hepatitis C; Contents; Contributors; Preface; Section I Foundations for Understanding Antiviral Therapies in HCV; 1 HCV Replication; 2 Hepatitis C Virus Genotypes; 3 Immune Responses to HCV: Implications for Therapy; 4 Mechanisms of Action of Antiviral Drugs: The Interferons; 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs; 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors; 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors; 8 Measuring Antiviral Responses
Section II Efficacy and Clinical Use of Antiviral Therapies9 Genotype 1: Standard Treatment; 10 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients; 11 Genotype 1 Relapsers and Non-responders; 12 Standard Therapy for Genotypes 2/3; 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3; 14 Genotypes 2 and 3 Relapse and Non-response; 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges; 16 Antivirals in Acute Hepatitis C; 17 Antivirals in Cirrhosis and Portal Hypertension 18 Treatment of Recurrent Hepatitis C Following Liver Transplantation19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations; 20 Cytopenias: How they Limit Therapy and Potential Correction; 21 The Problem of Insulin Resistance and its Effect on Therapy; 22 HIV and Hepatitis C Co-infection; 23 HCV and Racial Differences; 24 HCV and the Pediatric Population; 25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV; Index |
| Record Nr. | UNINA-9910139591503321 |
McCaughan Geoffrey W
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced Therapy for Hepatitis C [[electronic resource]]
| Advanced Therapy for Hepatitis C [[electronic resource]] |
| Autore | McCaughan Geoffrey W |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (233 p.) |
| Disciplina |
616.3/62306
616.362306 |
| Altri autori (Persone) |
McHutchisonJohn
PawlotskyJean-Michel |
| Soggetto topico |
Antiviral agents
Antiviral Agents - therapeutic use Antiviral Agents -- therapeutic use Hepatitis C - therapy Hepatitis C -- therapy Hepatitis C - Treatment Hepatitis C -- Treatment Hepatitis, Viral, Human Flaviviridae Infections Anti-Infective Agents RNA Virus Infections Therapeutic Uses Virus Diseases Hepatitis Diseases Liver Diseases Pharmacologic Actions Chemical Actions and Uses Digestive System Diseases Antiviral Agents Hepatitis C Medicine Health & Biological Sciences Gastroenterology |
| ISBN |
1-283-28323-9
9786613283238 1-4443-4634-2 1-4443-4631-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Advanced Therapy for Hepatitis C; Contents; Contributors; Preface; Section I Foundations for Understanding Antiviral Therapies in HCV; 1 HCV Replication; 2 Hepatitis C Virus Genotypes; 3 Immune Responses to HCV: Implications for Therapy; 4 Mechanisms of Action of Antiviral Drugs: The Interferons; 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs; 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors; 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors; 8 Measuring Antiviral Responses
Section II Efficacy and Clinical Use of Antiviral Therapies9 Genotype 1: Standard Treatment; 10 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients; 11 Genotype 1 Relapsers and Non-responders; 12 Standard Therapy for Genotypes 2/3; 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3; 14 Genotypes 2 and 3 Relapse and Non-response; 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges; 16 Antivirals in Acute Hepatitis C; 17 Antivirals in Cirrhosis and Portal Hypertension 18 Treatment of Recurrent Hepatitis C Following Liver Transplantation19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations; 20 Cytopenias: How they Limit Therapy and Potential Correction; 21 The Problem of Insulin Resistance and its Effect on Therapy; 22 HIV and Hepatitis C Co-infection; 23 HCV and Racial Differences; 24 HCV and the Pediatric Population; 25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV; Index |
| Record Nr. | UNINA-9910809498803321 |
|
McCaughan Geoffrey W
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910139613803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910808713803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
